(Q43261058)

17 November 2017

Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib (English)

1 reference

17 November 2017

Fengsheng Chen

1

1 reference

17 November 2017

Xi Luo

2

1 reference

17 November 2017

Jinbiao Zhang

3

1 reference

17 November 2017

Yang Lu

4

1 reference

17 November 2017

Rongcheng Luo

5

1 reference

17 November 2017

language of work or name

1 reference

15 October 2009

1 reference

17 November 2017

1 reference

17 November 2017

27

1 reference

17 November 2017

3

1 reference

17 November 2017

950-957

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-009-9315-8

17 November 2017

0 references

cites work

Overview of gefitinib in non-small cell lung cancer: an Asian perspective

1 reference

12 December 2020

Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer

1 reference

12 December 2020

Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE

1 reference

12 December 2020

A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study

1 reference

12 December 2020

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

1 reference

12 December 2020

Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib

1 reference

12 December 2020

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

1 reference

12 December 2020

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

12 December 2020

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

1 reference

12 December 2020

Classification, staging and prognosis of lung cancer

1 reference

12 December 2020

Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS

1 reference

12 December 2020

[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial]

1 reference

12 December 2020

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

12 December 2020

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung

1 reference

12 December 2020

Lung tumor markers of cytokeratin origin: an overview

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

12 December 2020

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer

1 reference

12 December 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

12 December 2020

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?

1 reference

12 December 2020

Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer

1 reference

12 December 2020

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer

1 reference

12 December 2020

Clinical utility of cytokeratins as tumor markers

1 reference

12 December 2020

Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer

1 reference

12 December 2020

Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments

1 reference

12 December 2020

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer

1 reference

12 December 2020

Cancer statistics, 2007

1 reference

12 December 2020

10.1007/S12032-009-9315-8

Identifiers

DOI

1 reference

Dimensions Publication ID

17 November 2017

0 references

1 reference